ISSN: 2581-5989
PubMed - National Library of Medicine - ID: 101738774

International Journal of Dental Science and Innovative Research (IJDSIR)

IJDSIR : Dental Publication Service

Available Online at: www.ijdsir.com

Volume – 5, Issue – 2, April - 2022, Page No. : 298 - 301

Levobupivacaine- A helping hand for dental surgeons

[1]Dr. Ananya Roy, Clinical Practitioner Department of Oral and Maxillofacial Surgery, Haldia Institute of Dental Sciences and Research.

[2]Dr. Mainak Ghosh, Post Graduate Trainee Department of Oral and Maxillofacial Surgery, Haldia Institute of Dental Sciences and Research.

Corresponding Author: Dr. Mainak Ghosh, Post Graduate Trainee Department of Oral and Maxillofacial Surgery, Haldia Institute of Dental Sciences and Research.

Citation of this Article: Dr. Ananya Roy, Dr. Mainak Ghosh, "Levobupivacaine- A helping hand for dental surgeons", IJDSIR- April - 2022, Vol. – 5, Issue - 2, P. No. 298 – 301.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Lignocaine 2% with adrenaline 1: 100,000 (Xylocaine) is appeared as the usual to which all other local anesthetics are as compared. [1] From the 1900 to recent times, although bupivacaine is used an awful lot, nevertheless levobupivacaine lagged in the back of though having less cardiotoxicity than bupivacaine.[2]

In latest years, levobupivacaine, the natural S (−)-enantiomer of bupivacaine, emerged as a more secure alternative for local anesthesia than its racemic discern. [3]

Keywords: levobupivacaine, bupivacaine, local anesthesia

Introduction

In the era of regional anesthesia, levobupivacaine emerged very quickly. Levobupivacaine is the s-isomer of racemic bupivacaine. It is less cardio, neurotoxic and equally potent local anaesthetic compared to its racemate. It is known to cause less depression of myocardial contractility. [2].

Pharmacodynamics

Levobupivacaine reversibly blocks the transmission of action potential by inhibiting the passage of sodium through voltage- sensitive ion channels.

Excessive dosage can lead to cardiovascular and CNS irregularities.

Pharmacokinetics

Volume of distribution and clearance in significantly lower that racemic isomer.[4]. However, unbound fraction being less which accounted for less toxicity. Post-operative increased alpha 1 glycoprotein binds with levobupivacaine further leading to its less toxicity profile.[5, 6]. Site of administration, duration of continuous infusion and/or addition of agents with vasomotor effect have an immense role on systemic uptake of levobupivacaine. [3].

History

Bupivacaine is a long-duration local anaesthetic. Bupivacaine shows good nerve anesthesia and does not

require the addition of epinephrine to prolong its effect which made its use more increasing time by time.[7.] But the main disadvantage of bupivacaine exposed in the form of cardiotoxicity. It was believed that local anaesthetic toxicity manifests as a progression from mild symptoms to convulsions, eventual cardiac depression and cardiac arrest. [8].

Stereochemistry

Bupivacaine toxicity has led to explore the area of stereochemistry. Differences between the bupivacaine isomers were first noted by Aberg and Luduena in 1972. [9,10]. It also revealed the increased efficacy of S (-) isomer after skin infiltration.

Effect on different systems

Cardiovascular system: Levobupivacaine tested less affinity and electricity of inhibitory effect onto the inactivated state of cardiac sodium channels than dextrobupivacaine.[11,12]. Interactions with the inactivated nation of the sodium channel showed marked stereoselectivity, with a 39% decrease EC50 for inactivated country block through dextrobupivacaine. [13]. Apparent dissociation consistent values of 27.3 mm and 4.1 mm were calculated for dextrobupivacaine and levobupivacaine, indicating dextrobupivacaine to be seven times more potent in blockading the potassium channel than levobupivacaine.[14]. Racemic bupivacaine caused a greater than 50% lower in Vmax compared to levobupivacaine and ropivacaine at 30 mm.[15]

Central nervous system: The standard deviation of convulsive dose after intravenous levobupivacaine in conscious sheep is 103 (18) mg, appreciably better than the convulsive dose of bupivacaine 85 (11) mg.[16].

The early scientific presentation of toxicity after levobupivacaine seems to consist of relevant anxious signs and symptoms (disorientation, drowsiness, slurred speech).[17, 18]

Role of levobupivacaine in dental surgery

Initial licensing of levobupivacaine recommends a dose of 150 mg and a maximum dose over 24 h of 400 mg. The expanded safety margin of levobupivacaine would possibly advocate that more drug might be administered in divided doses. Some studies have proven a small growth in length of sensory block with levobupivacaine. Although having a limited degree of clinical impact, this remark may be as a result of the extended relative vasoconstrictive movement of levobupivacaine as compared to bupivacaine.[19,20].The satisfactory of sensory and motor block seems to be comparable in most studies after same doses of levobupivacaine and bupivacaine Adding adjunctive analgesics together with epinephrine to local anesthetic also are used to enhance the quality of analgesia and improve safety via reducing the necessities of levobupivacaine.

The long period of sensory and motor peripheral blockade after levobupivacaine of approximate 14–16 hours diminish the scientific significance of including epinephrine to levobupivacaine. However, epinephrine may additionally assist decrease the potential for systemic toxicity in case of overdose by means of lowering systemic absorption through vasoconstriction or through signaling the accidental intravascular injection. Higher concentrations of levobupivacaine, i.e, 0.5%–0.75% speed up the onset, and increase the duration and quality of peripheral nerves blockade.

In addition, scientific studies all indicate that levo bupivacaine is properly tolerated and has an efficacy equivalent to bupivacaine for each anaesthesia and analgesia across a huge spectrum of indications, which include postoperative pain control.

Conclusion

In the end, we can safely conclude that levobupivacaine has an ampule efficacy and improved protection profile,

a main benefit in local anaesthesia. It is to be was hoping that the introduction of this new isomer might be a stepping stone closer to safer local anaesthetic practice.

References

1. Bouloux Gay E, Punnia-Moorthy Arumugam. Bupivacaine versus Lidocaine for Third Molar Surgery: A Double-Blind, Randomized, Crossover Study. J Oral Maxillofac Surg 57:510-514, 1999.
2. Satyanarayana LA, Heggeri Vijayakumar M, Simha PP, Narasimaiah Satish, Narasimaiah M, Subbarao BK. Comparison of Epidural Bupivacaine, Levobupivacaine and Dexmedetomidine in Patients Undergoing Vascular Surgery. J Clin Diagn Res. 2016 Jan; 10(1): UC13–UC17.
3. Burlacu CL, Buggy DJ. Update on local anesthetics: focus on levobupivacaine. Therapeutics and Clinical Risk Management 2008:4(2) 381–392.
4. Burm AG, van der Meer AD, van Kleef JW. Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. Br J Clin Pharmacology. 1994. 38:125–9.
5. Berris ford RG, Saba Nathan S, Mearns AJ. Plasma concentrations of bupivacaine and its enantiomers during continuous extra pleural intercostal nerve block. Br J Anaesthesia. 1993. 70:201–4.
6. Blake DW, Bjork ten A, Dawson P. Pharmacokinetics of bupivacaine enantiomers during interpleural infusion. Anaesth Intensive Care. 1994. 22:522–8.
7. Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51: 285±7.
8. Covino BG, Vassallo HG. In: Local Anesthetics: Mechanisms of Action and Clinical Use. New York: Grune and Stratton, 1976.
9. Aberg G. Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds. Acta Pharmacologic et Toxicologic 1972; 31: 273±86.
10. Luduena FP, Bog ado EF, Tullar BF. Optical Isomers of Mepivacaine and Bupivacaine. Archives of International Pharmacodynamics 1972; 200: 359±69.
11. Vanhouette F, Vereecke J, Verbeke N, et al. 1991. Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle. Br J Pharmacol, 103:1275–81.
12. Valenzuela C, Delpon E, Tamkun MM, et al. 1995b. Stereoselective block of a human cardiac potassium channel (K v 1.5) by bupivacaine enantiomers. Biopsy's J, 69:418–27.
13. Avery P, Redon D, Schaenzer G, et al. The influence of serum potassium on the cerebral and cardiac toxicity of bupivacaine and lidocaine. Anesthesiology 1984; 61: 134±8.
14. Valenzuela C, Delpon E, Tamkun MM, et al. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophysical Journal 1995; 69: 418±27.
15. Harding D, Collier P, Grist wood R, et al. Effects of levobupivacaine, bupivacaine and ropivacaine on contractility and electrophysiology of guinea-pig and human cardiac muscle in vitro. British Journal of Pharmacology.
16. Huang YF, Pryor ME, Mather LE. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. Anaesth Analg, 1998. 86:797–804.
17. Breslin DS, Martin G, Macleod DB. Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases. Reg Anaesth Pain Med. 2000. 28:144–7.

18. Crews JC, Rothman TE. Seizure after levobupivacaine for interscalene brachial plexus block. Anaesth Analg. 2003. 96:1188–90.

19. Cox CR, Checketts MR, Mackenzie N, et al. Comparison of S (-) -bupivacaine with racemic (RS) -bupivacaine in supraclavicular brachial plexus block. British Journal of Anaesthesia 1998; 80: 594±8.

20. Kopacz DJ, Sharrock NE, Allen HWA. Comparison of levobupivacaine 0.125%, fentanyl 4 microg/mL, or their combination for patient-controlled epidural analgesia after major orthopedic surgery. Anesthesia and Analgesia 1999; 89: 1497±503.